Literature DB >> 2444902

Selective agonists for substance P and neurokinin receptors.

G Drapeau1, P D'Orléans-Juste, S Dion, N E Rhaleb, N E Rouissi, D Regoli.   

Abstract

A series of neurokinin analogues and fragments have been prepared in an attempt to identify selective agonists for NK-P, NK-A and NK-B receptors. The compounds have been tested on the dog carotid artery (NK-P receptor system), the rabbit pulmonary artery (NK-A) and the rat portal vein (NK-B). C-terminal substituted analogues of the three neurokinins have provided indication that NK-P receptor selectivity is improved by the oxidation of methionine to Met(O2), while selectivity for NK-A is favoured by replacing Met with NIe. Selectivity for NK-P receptors is further improved by the replacement of Gly9 with Sar. Selectivity and affinity for NK-B receptors is markedly increased when Val7 is replaced with MePhe in both the fragment NKB (4-10) and NKB. The results of the present study indicate that a) [Sar9,Met(O2)11]SP is a potent and selective agonist for the NK-P receptors of the dog carotid artery; b) [MePhe7]NKB is a very potent and selective stimulant of receptors for neurokinin B and c) [Nle10]NKA (4-10) is a promising compound, showing some selectivity for NK-A receptor; further modifications are however needed to improve its affinity.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2444902     DOI: 10.1016/0143-4179(87)90088-6

Source DB:  PubMed          Journal:  Neuropeptides        ISSN: 0143-4179            Impact factor:   3.286


  44 in total

1.  Tachykinin-induced contraction of the guinea-pig isolated oesophageal mucosa is mediated by NK(2) receptors.

Authors:  K P Kerr; B Thai; I M Coupar
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

2.  Functional characterization of tachykinin NK1 receptors in the mouse uterus.

Authors:  Eva Patak; Jocelyn N Pennefather; Anna Fleming; Margot E Story
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

3.  CP-96,345, a non-peptide antagonist of substance P: I. Effects on the actions mediated by substance P and related tachykinins on the guinea-pig ileum and rabbit jejunum.

Authors:  F J Legat; T Griesbacher; F Lembeck
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-09       Impact factor: 3.000

4.  Regional variations in neurokinin receptor subtype contributions to muscularis mucosae and epithelial function in rat colon.

Authors:  Caroline B Appleyard; Marangelie Morales; William H Percy
Journal:  Dig Dis Sci       Date:  2006-03       Impact factor: 3.199

5.  NK1 receptors mediate tachykinin-induced plasma extravasation in the rat knee joint.

Authors:  Y Hirayama; R Yasumitsu; A Kawamura; T Fujii
Journal:  Agents Actions       Date:  1993-11

6.  Inhibition of tachykinin-induced hypotension in dogs by CP-96,345, a selective blocker of NK-1 receptors.

Authors:  J W Constantine; W S Lebel; H A Woody
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-10       Impact factor: 3.000

7.  Effect of SR 142801 on nitric oxide-dependent and independent responses to tachykinin NK3 receptor agonists in isolated guinea-pig colon.

Authors:  S Giuliani; C A Maggi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-11       Impact factor: 3.000

8.  Evidence for a GABA(B) receptor component in the spinal action of Substance P (SP) on arterial blood pressure in the awake rat.

Authors:  Jonathan Brouillette; Réjean Couture
Journal:  Br J Pharmacol       Date:  2002-08       Impact factor: 8.739

9.  Modulation of cortical acetylcholine release by serotonin: the role of substance P interneurons.

Authors:  T J Feuerstein; O Gleichauf; G B Landwehrmeyer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-11       Impact factor: 3.000

10.  Study of SR 142801, a new potent non-peptide NK3 receptor antagonist on cardiovascular responses in conscious guinea-pig.

Authors:  A Roccon; D Marchionni; D Nisato
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.